MOSCOW (Sputnik) – A coronavirus vaccine developed by the US-based Novavax company has demonstrated an 89.3-percent efficacy during phase 3 trials conducted in the United Kingdom, the company said in a statement.
MOSCOW (Sputnik) – A coronavirus vaccine developed by the US-based Novavax company has demonstrated an 89.3-percent efficacy during phase 3 trials conducted in the United Kingdom, the company said in a statement.
